BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare
disorders, today announced that Sanj K. Patel, President and Chief
Executive Officer, will present at the Morgan Stanley Global Healthcare
Conference in New York City on Tuesday, September 11, 2012, at 9:10 a.m.
EDT. Carsten Boess, Synageva’s Chief Financial Officer, will present at
the ThinkEquity Growth Conference, also in New York City, on Wednesday,
September 12, 2012 at 9:15 a.m. EDT.
The presentations for both conferences will be webcast live and may be
accessed from the “Webcasts & Presentations” section of the Investor
Relations tab on the home page of Synageva’s website at www.synageva.com.
About Synageva’s Lead Program
is a recombinant form of the human LAL enzyme being developed as an
enzyme replacement therapy for Lysosomal Acid Lipase (LAL) Deficiency, a
lysosomal storage disorder (LSD). SBC-102 is currently being evaluated
in global clinical trials and has been granted orphan designations by
the U.S. Food and Drug Administration (“FDA”), the European Medicines
Agency, and the Japanese Ministry of Health, Labour and Welfare.
Additionally, SBC-102 received fast track designation by the FDA.
About LAL Deficiency
Acid Lipase Deficiency is a rare, autosomal recessive LSD that is
caused by a marked decrease in LAL enzyme activity. Late onset LAL
Deficiency, sometimes called Cholesteryl Ester Storage Disease (CESD),
affects both children and adults. In these patients, the buildup of
fatty material in the liver, spleen and blood vessel walls leads to
complications resulting in significant morbidity and mortality. Early
onset LAL Deficiency, sometimes called Wolman disease, affects infants
in the first year of life and is characterized by growth failure,
malabsorption, steatorrhea and hepatomegaly and is rapidly fatal,
usually within the first year of life.
About Synageva BioPharma Corp.
Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and commercialization of therapeutic products
for patients with life-threatening rare diseases and unmet medical need.
Synageva has several protein therapeutics in its pipeline.
The company has assembled a team with a proven record of bringing orphan
therapies to patients.
Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.
This news release and oral statements made from time to time by Synageva
representatives in respect of the same subject matter may contain
“forward-looking statements” under the provisions of the Private
Securities Litigation Reform Act of 1995. Such statements can be
identified by introductory words such as “expects,” “plans,” “intends,”
“believes,” “will,” “estimates,” “forecasts,” “projects,” or words of
similar meaning, and by the fact that they do not relate strictly to
historical or current facts. Many factors may cause actual results to
differ materially from forward-looking statements, including inaccurate
assumptions and a broad variety of risks and uncertainties, some of
which are known, including those identified under the heading “Risk
Factors” in the Company’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission (the “SEC”) on March 22, 2012 and
other filings the Company periodically makes with the SEC, and others of
which are not. Synageva cannot be sure when or if it will be permitted
by regulatory agencies to undertake additional clinical trials or to
commence any particular phase of clinical trials or how quickly patient
enrollment in clinical trials will occur. In addition, early clinical
results are not necessary predictive of results that may be achieved
from subsequent clinical trials. Because of this, statements regarding
the expected timing of clinical trials or ultimate regulatory approval
cannot be regarded as actual predictions of when Synageva will obtain
regulatory approval for any phase of clinical trials or when it will
obtain ultimate regulatory approval by a particular regulatory agency.
Our future financial results may differ from those currently anticipated
due to a number of factors, including unanticipated costs in our
research and development programs, fluctuations in royalty revenues and
unplanned costs associated with maintaining and enforcing patents and
other patent-related costs. No forward-looking statement is a guarantee
of future results or events, and one should avoid placing undue reliance
on such statements. Synageva undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information,
future events or otherwise.